Agentix Corp. (AGTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Agentix Corp. (AGTX) trades at $0.02 with AI Score 47/100 (Grade C). Agentix Corp. (AGTX) is a clinical development stage biotechnology company focused on therapeutics for metabolic diseases. Market cap: $801,339, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for AGTX: AGTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AGTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AGTX: the 1 perspectives are evenly split.
How is this calculated? →Agentix Corp. (AGTX) Healthcare & Pipeline Overview
Agentix Corp. is a clinical development stage biotechnology firm specializing in therapeutics for metabolic diseases, with a focus on innovative treatments targeting obesity and type 2 diabetes through its proprietary product pipeline.
What Is the Investment Thesis for AGTX?
Agentix Corp. presents a compelling investment thesis based on its innovative product pipeline targeting major metabolic diseases, particularly obesity and type 2 diabetes. The company's lead candidates, AGTX-2004 and AGTX-2003, have demonstrated promising efficacy in preclinical studies, positioning Agentix to capitalize on the growing demand for effective metabolic disease treatments. The global obesity treatment market is projected to reach approximately $60 billion by 2026, providing a substantial growth opportunity for Agentix if its products receive regulatory approval. The company's strategic focus on peripherally-acting CB1 receptor modulators could differentiate its offerings in a crowded market, potentially leading to significant revenue generation upon successful commercialization. However, investors should remain aware of the inherent risks associated with clinical development, including regulatory hurdles and the need for substantial funding to support ongoing trials.
Based on FMP financials and quantitative analysis
AGTX Key Highlights
- Market Cap: $0.00B, indicating early-stage development status.
- Beta: 0.92, suggesting lower volatility compared to the broader market.
- Dividend Yield: None, as the company is reinvesting in R&D.
- Product pipeline includes AGTX-2004 and AGTX-2003, targeting obesity and type 2 diabetes.
- Formerly known as FairWind Energy, Inc., indicating a significant pivot in business strategy.
Who Are AGTX's Competitors?
AGTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| NVO Novo Nordisk A/S | $49.28 | -2.27% | $219.01B | 51 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AGTX's Key Strengths?
- Innovative product pipeline with potential for significant market impact.
- Experienced leadership team with a focus on clinical development.
- Strategic location in California, a hub for biotechnology.
What Are AGTX's Weaknesses?
- Limited financial resources typical of clinical development stage companies.
- Dependence on successful clinical trial outcomes for future growth.
- Lack of established market presence compared to larger competitors.
What Could Drive AGTX Stock Higher?
- Results from clinical trials for AGTX-2004 and AGTX-2003 expected in the next 12 months.
- Development of partnerships with pharmaceutical companies to enhance research capabilities.
- Continuous monitoring of market trends in obesity and metabolic diseases to align product development.
What Are the Key Risks for AGTX?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles that may delay product approvals.
- Competition from established firms with more resources.
- Financial risks associated with the need for ongoing funding for clinical trials.
What Are the Growth Opportunities for AGTX?
- Growth opportunity 1: The global obesity treatment market is projected to reach $60 billion by 2026, driven by increasing prevalence rates and a growing emphasis on effective therapeutic interventions. Agentix's focus on innovative CB1 receptor modulators positions it to capture a share of this expanding market, particularly if clinical trials yield positive results and lead to regulatory approvals.
- Growth opportunity 2: Agentix's AGTX-2004 and AGTX-2003 products target significant unmet medical needs in obesity and type 2 diabetes, two of the most pressing health challenges globally. As healthcare providers seek effective solutions for these conditions, Agentix's innovative approach could attract partnerships with larger pharmaceutical companies looking to expand their metabolic disease portfolios.
- Growth opportunity 3: The increasing awareness and diagnosis of metabolic diseases present a favorable environment for Agentix's product pipeline. As healthcare systems worldwide prioritize preventive care and chronic disease management, the demand for effective therapeutics is expected to rise, providing a robust market for Agentix's offerings.
- Growth opportunity 4: Collaborations with research institutions and healthcare organizations could enhance Agentix's clinical development efforts, accelerating the path to market for its product candidates. Strategic partnerships may also provide access to additional funding, expertise, and resources necessary for successful commercialization.
- Growth opportunity 5: The ongoing advancements in biotechnology, including personalized medicine and targeted therapies, create an opportunity for Agentix to leverage its innovative research in developing tailored treatments for metabolic diseases. This could enhance the company's competitive positioning and drive long-term growth.
What Opportunities Does AGTX Have?
- Growing global demand for effective obesity treatments.
- Potential for partnerships with larger pharmaceutical companies.
- Increased awareness and diagnosis of metabolic diseases.
What Threats Does AGTX Face?
- Intense competition from established biotechnology firms.
- Regulatory hurdles and challenges in clinical trial approvals.
- Market volatility affecting funding and investment opportunities.
What Are AGTX's Competitive Advantages?
- Innovative product pipeline targeting significant health challenges.
- Focus on peripherally-acting CB1 receptor modulators differentiates from competitors.
- Strong potential for partnerships with larger pharmaceutical firms.
- Ability to address unmet medical needs in the obesity treatment market.
What Does AGTX Do?
Agentix Corp., incorporated in 2013 and based in Dana Point, California, is a clinical development stage biotechnology company dedicated to the development and commercialization of therapeutics aimed at treating metabolic diseases. The company was formerly known as FairWind Energy, Inc. and rebranded to Agentix Corp. in June 2019, marking a strategic pivot towards the healthcare sector. Agentix's product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has shown efficacy in animal models for obesity and type 2 diabetes mellitus, and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models for obesity and non-alcoholic fatty liver diseases. With a focus on innovative therapeutic solutions, Agentix is positioned to address significant unmet medical needs in the metabolic disease space. The company is currently navigating the clinical development landscape, aiming to advance its product candidates through various stages of trials to achieve regulatory approval and commercialization. As a clinical development stage entity, Agentix is actively seeking partnerships and collaborations to enhance its research capabilities and expand its market reach.
What Products and Services Does AGTX Offer?
- Develops therapeutics for metabolic diseases.
- Focuses on peripherally-acting CB1 receptor modulators.
- Conducts preclinical and clinical trials to evaluate product efficacy.
- Seeks partnerships for research and development.
- Aims to address obesity and type 2 diabetes treatment gaps.
- Operates within the biotechnology sector, targeting unmet medical needs.
How Does AGTX Make Money?
- Generates revenue through the commercialization of therapeutics.
- Engages in partnerships and collaborations for research funding.
- Invests in clinical trials to advance product candidates.
- Focuses on innovative solutions to meet healthcare demands.
- Seeks to capture market share in the growing obesity treatment sector.
What Industry Does AGTX Operate In?
The biotechnology industry, particularly within the healthcare sector, is experiencing rapid growth driven by advancements in technology and an increasing focus on personalized medicine. The global market for obesity treatments is projected to grow significantly, with rising obesity rates contributing to the demand for effective therapeutic options. Agentix Corp. operates in a competitive landscape that includes established players and emerging biotech firms focused on metabolic diseases. As the industry evolves, companies that can demonstrate clinical efficacy and navigate regulatory pathways effectively are poised for success.
Who Are AGTX's Key Customers?
- Healthcare providers seeking effective metabolic disease treatments.
- Pharmaceutical companies interested in collaboration.
- Patients suffering from obesity and type 2 diabetes.
- Research institutions focused on metabolic disease studies.
- Investors looking for opportunities in biotechnology.
Company Profile
Agentix Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dana Point, US. The company is led by CEO Riazul Huda. AGTX has traded publicly since 2015.
F-Score 1/9Financial Health
Agentix Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 18%Key Financial Metrics
Return on equity for Agentix Corp. stands at 17.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -18.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.3%, the inverse of the P/E and a quick read on earnings relative to price.
AGTX Valuation & Market Position
With a 801K market cap, Agentix Corp. sits in the micro-cap segment of the market. Relative to its peer group, AGTX's quantitative score of 47/100 is below the peer average of 77/100.
AGTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Innovative product pipeline with potential for significant market impact.
- Experienced leadership team with a focus on clinical development.
- Strategic location in California, a hub for biotechnology.
- Upcoming: Results from clinical trials for AGTX-2004 and AGTX-2003 expected in the next 12 months.
Bear Case
- Limited financial resources typical of clinical development stage companies.
- Dependence on successful clinical trial outcomes for future growth.
- Lack of established market presence compared to larger competitors.
- Potential: Regulatory hurdles that may delay product approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
AGTX Latest News
No recent news available for AGTX.
AGTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AGTX.
Price Targets
Wall Street price target analysis for AGTX.
AGTX MoonshotScore
What does this score mean?
The MoonshotScore rates AGTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Riazul Huda
CEO
Riazul Huda has extensive experience in the biotechnology sector, having held various leadership roles in clinical development and strategic management. He holds a degree in Biotechnology and has a proven track record of guiding companies through the complexities of drug development and commercialization.
Track Record: Under Riazul Huda's leadership, Agentix Corp. has successfully transitioned from FairWind Energy, Inc. to a focused biotechnology firm, advancing its product pipeline and establishing a clear strategic direction.
AGTX OTC Market Information
Agentix Corp. trades on the OTC Other tier, which includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier often comprises smaller, less liquid stocks, which may present unique investment opportunities and risks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can lead to difficulty in executing trades.
- Less stringent reporting requirements may result in less transparency.
- Higher volatility compared to stocks listed on major exchanges.
- Verify the company's financial health and funding status.
- Assess the progress of clinical trials and product development.
- Review management's track record and industry experience.
- Evaluate the competitive landscape and market potential.
- Consider the company's strategic partnerships and collaborations.
- Established leadership team with relevant industry experience.
- Clear focus on addressing significant health challenges.
- Active engagement in clinical trials and research initiatives.
Common Questions About AGTX (Healthcare)
What does Agentix Corp. do?
Agentix Corp. is a biotechnology company focused on developing therapeutics for metabolic diseases, particularly obesity and type 2 diabetes. The company is advancing its product pipeline, which includes AGTX-2004 and AGTX-2003, both of which have shown promising efficacy in preclinical studies. Agentix aims to address significant unmet medical needs in these areas through innovative therapeutic solutions.
What are the main risks for AGTX?
Agentix Corp. faces several risks, including regulatory hurdles that could delay the approval of its product candidates, particularly AGTX-2004 and AGTX-2003. Additionally, the company operates in a highly competitive environment, where established firms may have more resources and market presence. Financial risks are also a concern, as ongoing funding is necessary to support clinical trials and development efforts.
How does Agentix Corp. manage patent expiration risks?
Agentix Corp. is focused on developing innovative therapeutics that target significant health challenges, which may help mitigate patent expiration risks. The company invests in research and development to create novel compounds with unique mechanisms of action, thereby extending the lifecycle of its products. Additionally, Agentix may explore strategic partnerships to enhance its portfolio and ensure a continuous flow of innovative therapies.
What are the key factors to evaluate for AGTX?
Agentix Corp. (AGTX) holds an AI score of 47/100 (low). Not financial advice.
How frequently does AGTX data refresh on this page?
AGTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AGTX's recent stock price performance?
Agentix Corp. (AGTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with potential for significant market impact. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AGTX overvalued or undervalued right now?
Valuing Agentix Corp. (AGTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AGTX?
Before investing in Agentix Corp. (AGTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC classification.